1,3-二氢呋喃并[3,4-C]吡啶 | 126230-90-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1,3-二氢呋喃并[3,4-C]吡啶
• 英文名称: 1,3-dihydrofuro[3,4-c]pyridine
• 英文别名: 1,3-dihydrofuro<3,4-c>pyridine
• CAS: 126230-90-8
• 化学式: C₇H₇NO
• 分子量: 121.139
• InChiKey: WBNLAHSOVLAWCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,3-二氢呋喃并[3,4-C]吡啶 在 iron(II) triflate 、 2-((4R,5R)-1-((4-(tert-butyl)phenyl)sulfonyl)-4,5-diphenylimidazolidin-2-yl)-6-((4R,5R)-1-((4-(tert-butyl)phenyl)sulfonyl)-4,5-diphenylimidazolidin-2-yl)pyridine 、 氧气 作用下， 60.0 ℃ 、101.33 kPa 条件下， 反应 16.0h， 以19%的产率得到呋喃并[3,4-c]吡啶-1(3h)-酮
  参考文献：
  名称：

  Dehydrogenative α-Oxygenation of Ethers with an Iron Catalyst

  摘要：

  Selective alpha-oxidation of ethers under aerobic conditions is a long-pursued transformation; however, a green and efficient catalytic version of this reaction remains challenging. Herein, we report a new family of iron catalysts capable of promoting chemoselective alpha-oxidation of a range of ethers with excellent mass balance and high turnover numbers under 1 atm of O-2 with no need for any additives. Unlike metalloenzymes and related biomimetics, the catalyst produces H-2 as the only byproduct. Mechanistic investigations provide evidence for an unexpected two-step reaction pathway, which involves dehydrogenative incorporation of O-2 into the ether to give a peroxobisether intermediate followed by cleavage of the peroxy bond to form two ester molecules, releasing stoichiometric H-2 gas in each step. The operational simplicity and environmental friendliness of this methodology affords a useful alternative for performing oxidation, while the unique ability of the catalyst in oxygenating a substrate via dehydrogenation points to a new direction for understanding metalloenzymes and designing new biomimetic catalysts.

  DOI：

  10.1021/ja502167h
• 作为产物：
  描述：

  2-((prop-2-yn-1-yloxy)methyl)pyrazine 以 三氟乙酸 为溶剂， 反应 0.33h， 以88%的产率得到1,3-二氢呋喃并[3,4-C]吡啶
  参考文献：
  名称：

  季吡嗪鎓盐和质子化吡嗪鎓阳离子的分子内Diels-Alder反应。退火的吡啶鎓盐和退火的吡啶的合成。

  摘要：

  如13 C NMR数据所示，炔基取代的吡嗪在二氯甲烷中用四氟硼酸三乙基氧鎓进行季铵化仅在N-4处产生3-炔基-1-乙基吡嗪鎓盐。同样的吡嗪与三氟乙酸的质子化也发生在N-4处。季吡嗪鎓盐以及质子化的吡嗪在比相应的中性吡嗪温和得多的条件下进行分子内Diels-Alder反应。反应产物分别为[ ]-退火的季吡啶鎓盐和[ ]-退火的质子化吡啶鎓阳离子。

  DOI：

  10.1016/s0040-4020(01)89528-4

文献信息

• NEW BIS-AMIDO PYRIDINES
  申请人：REISER Ulrich

  公开号：US20150057286A1

  公开（公告）日：2015-02-26

  This invention relates to bis-amido pyridines of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R 1 to R 4 have the meanings given in the claims and in the specification.

  这项发明涉及一般式（I）的双酰胺吡啶，其作为SMAC模拟物的用途，含有它们的药物组合物，以及它们作为治疗和/或预防由细胞过度或异常增殖引起的疾病及相关症状（如癌症）的药物的用途。R1至R4基团的含义如索赔和说明书中所述。
• [EN] 1,3 DIHYDROFURO [3,4-c]PYRIDINES AND THEIR PREPARATION<br/>[FR] 1,3 DIHYDROFURO [3,4-C]PYRIDINES ET PROCEDE PERMETTANT DE LES PREPARER
  申请人：DSM IP ASSETS BV

  公开号：WO2005090356A1

  公开（公告）日：2005-09-29

  The present invention relates to novel 1,3-dihydrofuro[3,4-c]pyridines which are useful intermediates in the synthesis of pyridoxines and a method for their preparation by cobalt(I) complex-catalysed [2 + 2 + 2]-cycloaddition of di-[(3-dimethyl-C1-4-alkoxysilyl)­2-propynyl)] ethers with acetonitrile.

  本发明涉及新型1,3-二氢呋喃[3,4-c]吡啶，该吡啶是有用的中间体，用于合成维生素B6（吡哆醇），以及一种通过钴(I)配合物催化的[2 + 2 + 2]-环加成反应，将二[(3-二甲基-C1-4-烷氧基硅基)-2-丙炔基]醚与乙腈制备它们的方法。
• [EN] NEW BIS-AMIDO PYRIDINES<br/>[FR] NOUVEAUX BIS-AMIDO PYRIDINES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015025018A1

  公开（公告）日：2015-02-26

  This invention relates to bis-amidopyridinesof general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R4 have the meanings given in the claims and in the specification.

  这项发明涉及一般式（I）的双酰胺吡啶类化合物，它们作为SMAC模拟物的用途，含有它们的药物组合物，以及它们作为治疗和/或预防由细胞过度或异常增殖引起的疾病及相关症状（如癌症）的药物的用途。基团R1到R4的含义如权利要求和说明书中所述。
• CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：Liu Qingjie

  公开号：US20100160303A1

  公开（公告）日：2010-06-24

  Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including Btk modulation.

  具有化学式(I)的化合物，以及其对映体、非对映异构体、药用可接受的盐，可用作激酶调节剂，包括Btk调节。
• [EN] SPIROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS SPIROCYCLIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2012009217A1

  公开（公告）日：2012-01-19

  Described herein are compounds of formula (I) (Formula (I)). The compounds of formula (I) act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

  本文描述了式（I）（化学式（I））的化合物。式（I）的化合物作为DGAT1抑制剂，可用于预防、治疗或作为高脂血症、糖尿病和肥胖的疗效剂。